Cervical cancer: Novel treatment strategies offer renewed optimism
Gangotri yadav,
Ganga Srinivasan,
Ashish Jain
и другие.
Pathology - Research and Practice,
Год журнала:
2024,
Номер
254, С. 155136 - 155136
Опубликована: Янв. 15, 2024
Язык: Английский
FOLFOX-HAIC combined with PD-1 inhibitor immunotherapy significantly improves survival in patients with advanced hepatocellular carcinoma
American Journal of Translational Research,
Год журнала:
2025,
Номер
17(4), С. 2577 - 2590
Опубликована: Янв. 1, 2025
To
evaluate
the
effect
of
FOLFOX-HAIC
combined
with
PD-1
inhibitor
immunotherapy
on
survival
patients
advanced
hepatocellular
carcinoma
(HCC).
This
retrospective
study
analyzed
137
HCC,
which
71
received
chemotherapy
(control
group)
and
66
inhibitors
(research
between
January
2020
August
2021.
Propensity
score
matching
(PSM)
was
employed
to
account
for
confounding
variables.
Cox
regression
analysis
utilized
identify
independent
risk
factors
that
sabotaged
patients'
survival,
Kaplan-Meier
curves
were
applied
demonstrate
overall
(OS).
A
significantly
higher
disease
control
rate
(DCR)
observed
in
research
group
than
(77.27%
vs.
60.56%,
P
=
0.035).
Prior
PSM
analysis,
OS
calculated
be
25
months,
14
months
(P
0.015).
While
post
median
turned
out
27
group,
still
comparison
0.001),
whose
months.
By
multivariate
maximum
tumor
diameter,
Eastern
Cooperative
Oncology
Group
Performance
Status
score,
treatment
regimen
identified
as
affecting
prognosis.
can
prolong
HCC.
Apparently,
this
therapy
is
advantageous
at
extending
patient's
time
use
alone.
Язык: Английский
Interactions in hepatic tumor microenvironment: Potential targets and modulations for effective therapy
Pathology - Research and Practice,
Год журнала:
2025,
Номер
unknown, С. 156074 - 156074
Опубликована: Июнь 1, 2025
Язык: Английский
REVIEWING ADVANCES IN UNDERSTANDING AND TARGETING THE MAPK SIGNALING PATHWAY IN HEPATOCELLULAR CARCINOMA PROGRESSION AND THERAPEUTICS
Agrobiological Records,
Год журнала:
2024,
Номер
15, С. 103 - 116
Опубликована: Янв. 1, 2024
Hepatocellular
carcinoma
(HCC)
is
a
severe
and
increasingly
prevalent
health
issue
affecting
individuals
globally.
Recent
research
endeavors
in
the
clinical
domains
have
lately
focused
more
on
MAPK
signaling
pathway
HCC.
Activating
mutations
RAS
RAF
genes,
which
greatly
activate
malignancies,
are
rare
HCC
patients,
yet
over
50%
of
them
activated
pathway.
This
suggests
that
other
factors
may
be
responsible
for
activation
important
to
carcinogenesis,
it
often
altered
human
cancers.
The
drug
resistance
targeted
therapy
against
RTKs
arise
from
downstream
components
(RAS,
RAF,
MEK,
ERK),
resistant
within
RTKs,
additional
alternative
pathways
like
PI3K
YAP
also
develop
resistance.
Epigenetic
processes
chromatin
remodeling
crucial
pharmacological
tolerance
regulation.
review
will
focus
latest
developments
our
knowledge
cellular
molecular
pathway,
as
well
possible
treatment
approaches
specifically
target
this
relation
study
investigates
efficacy
molecular-targeted
treatments,
including
tyrosine
kinase
inhibitors
immunological
checkpoint
highlights
use
combination
Язык: Английский
Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma
Journal of Ethnopharmacology,
Год журнала:
2024,
Номер
334, С. 118540 - 118540
Опубликована: Июль 9, 2024
Язык: Английский
Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review
Experimental and Therapeutic Medicine,
Год журнала:
2024,
Номер
27(5)
Опубликована: Март 12, 2024
Treatment
with
immune
checkpoint
inhibitors
(ICIs)
is
steadily
becoming
the
standard
of
care
for
hepatocellular
carcinoma
(HCC),
an
increasing
number
immune‑related
adverse
events
(irAEs).
However,
only
a
small
reports
on
occurrence
diabetes
mellitus
(DM)
in
patients
HCC
treated
ICIs
have
been
published.
In
present
study,
clinical
manifestations,
laboratory
findings,
treatment
and
prognosis
three
advanced
were
reported,
who
suffered
DM
when
receiving
ICIs.
Furthermore,
relevant
literature
was
reviewed
order
to
summarize
possible
mechanisms,
diagnosis,
rechallenge
recommended
management
options,
as
well
suggestions.
ICI‑induced
rare
but
irAEs
are
potentially
fatal,
diabetic
ketoacidosis
(DKA)
often
first
manifestation.
The
incidence
0.86%
among
those
cases,
DKA
59%.
combination
two
markedly
increases
risk.
human
leukocyte
antigen
genotype,
islet
autoantibodies
autoreactive
T
cell‑mediated
β‑cell
destruction
may
be
linked
DM.
Patient
education
clinicians'
awareness
ICI‑related
good
options.
Adequate
judgment,
close
monitoring
early
detection
also
needed
decide
whether
continue
immunotherapy
or
it,
so
achieve
maximum
benefit
treatment.
Язык: Английский
Advances in Immune Checkpoint Therapy in Hepatocellular Carcinoma
British Journal of Hospital Medicine,
Год журнала:
2024,
Номер
unknown, С. 1 - 21
Опубликована: Сен. 30, 2024
The
incidence
and
lethality
of
hepatocellular
carcinoma
(HCC)
are
increasing
annually,
traditional
treatments
have
been
proven
to
be
ineffective
for
patients
with
advanced
stages
the
disease.
In
recent
years,
immune
checkpoint
therapy
has
rapidly
evolved,
demonstrating
promising
results
across
a
wide
range
cancers
offering
new
hope
cancer
treatment.
However,
efficacy
in
HCC
varies
greatly
among
individuals,
only
small
proportion
responding
positively.
A
major
cause
resistance
poor
is
evasion,
which
often
due
insufficient
infiltration
cells.
Understanding
mechanisms
underlying
evasion
crucial
enhancing
therapies.
this
review,
we
aim
summarize
observed
during
discuss
future
directions
therapeutic
approach.
Our
goal
provide
insights
that
could
help
overcome
thereby
improving
therapies
extending
patient
survival
time.
Язык: Английский